Epic Bio to Participate in the BMO Virtual Spotlight Series

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022.

Amber Salzman, Ph.D., chief executive officer, and Dan Hart, Ph.D., head of technology development, are scheduled to participate in a fireside chat from 11:00 – 11:25 am ET.

About Epic Bio

Epic Bio is a leading epigenome engineering company leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information, or follow us on Twitter and LinkedIn.

Contacts

Investor Contact
Jessica Vo

Gilmartin Group, LLC

[email protected]

Media Contact
Lisa Raffensperger

Ten Bridge Communications

[email protected]
(617) 903-8783